Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul;24(7):617-22. doi: 10.18553/jmcp.2018.24.7.617
Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.
Feldman S, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3-a):S84.